The inhibitory effect of 111In-DTPA0-octreotide on intrahepatic tumor growth after partial hepatectomy

Journal of Nuclear Medicine

Volumn 43, Issue 12, 2002, Pages 1681-1687

  Slooter, Gerrit D ^a   Aalbers, Arend G J ^a   Breeman, Wouter A P ^a   Hiemstra, Coen A ^a   Marquet, Richard L ^a   Krenning, Eric P ^a   Van Eijck, Casper H J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

111In DTPA0 octreotide; Liver metastases; Partial hepatectomy; Peptide receptor radionuclide therapy

Indexed keywords

INDIUM 111; OCTREOTIDE; PENTETIC ACID; PEPTIDE; RADIOISOTOPE; RECEPTOR; SOMATOSTATIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; LIVER FUNCTION; LIVER METASTASIS; LIVER REGENERATION; LIVER RESECTION; MALE; NONHUMAN; PARTIAL HEPATECTOMY; PORTAL VEIN; PRIORITY JOURNAL; RAT; SURGICAL TECHNIQUE; TIME; TREATMENT INDICATION; TUMOR GROWTH;

ANIMALS; HEPATECTOMY; INDIUM RADIOISOTOPES; LIVER NEOPLASMS, EXPERIMENTAL; LIVER REGENERATION; MALE; OCTREOTIDE; PENTETIC ACID; RADIOPHARMACEUTICALS; RATS; RATS, INBRED LEW; RECEPTORS, SOMATOSTATIN;

EID: 0036900005     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Reichlin S. Somatostatin (second of two parts). N Engl J Med. 1983;309:1556-1563.
2. Kvols LK, Moertel CG, O'Connell MJ, Schutt AJ, Rubin J, Hahn RG. Treatment of the malignant carcinoid syndrome: Evaluation of a long-acting somatostatin analogue. N Engl J Med. 1986;315:663-666.
3. Weckbecker G, Liu R, Tolcsvai L, Bruns C. Antiproliferative effects of the somatostatin analogue octreotide (SMS 201-995) on ZR-75-1 human breast cancer cells in vivo and in vitro. Cancer Res. 1992;52:4973-4978.
4. Ruszniewski P, Lehy T, Reyl-Desmars F, Le Roux S, Lewin MJ. Octreotide (SMS 201-995) inhibits the growth of colon peritoneal carcinomatosis in BDIX rats. Regul Pept. 1993;43:141-147.
5. van Eijck CH, Slooter GD, Hofland LJ, et al. Somatostatin receptor-dependent growth inhibition of liver metastases by octreotide. Br J Surg. 1994;81:13331337.
6. Breeman WA, de Jong M, Kwekkeboom DJ, et al. Somatostatin receptor-mediated imaging and therapy: Basic science, current knowledge, limitations and future perspectives. Eur J Nucl Med. 2001;28:1421-1429.
7. 123I- Tyr3]-octreotide: The Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20:716-731.
8. Howell RW. Radiation spectra for Auger-electron emitting radionuclides: Report no. 2 of AAPM Nuclear Medicine Task Group No. 6. Med Phys. 1992;19:1371-1383.
9. Bass LA, Lanahan MV, Duncan JR, et al. Identification of the soluble in vivo metabolites of indium-111-diethylenetriaminepentaacetic acid-D-Phe1-octreotide. Bioconjug Chem. 1998;9:192-200.
10. Slooter GD, Breeman WA, Marquet RL, Krenning EP, van Eijck CH. Antiproliferative effect of radiolabelled octreotide in a metastases model in rat liver. Int J Cancer. 1999;81:767-771.
11. Slooter GD, Marquet RL, Jeekel J, Ijzermans JN. Tumour growth stimulation after partial hepatectomy can be reduced by treatment with tumour necrosis factor alpha. Br J Surg. 1995;82:129-132.
12. Roebuck BD, Yager JD Jr, Longnecker DS. Dietary modulation of azaserine-induced pancreatic carcinogenesis in the rat. Cancer Res. 1981;41:888-893.
13. Marquet RL, Westbroek DL, Jeekel J. Interferon treatment of a transplantable rat colon adenocarcinoma: Importance of tumor site. Int J Cancer. 1984;33:689-692.
14. Grenier JF, Marescaux J, Stock C, Coumaros G, Sava P, Michel F. BSP clearance as the most reliable criterion of hepatic dysfunction after jejunoileal bypass in the rat: Arguments in favor of the existence of a pathogenetic mechanism involving a transient malnutrition state. Dig Dis Sci. 1981;26:334-341.
15. Fong Y, Cohen AM, Fortner JG, et al. Liver resection for colorectal metastases. J Clin Oncol. 1997;15:938-946.
16. Scheele J, Stang R, Altendorf-Hofmann A, Paul M. Resection of colorectal liver metastases. World J Surg. 1995;19:59-71.
17. Hughes KS, Simon R, Songhorabodi S, et al. Resection of the liver for colorectal carcinoma metastases: A multi-institutional study of patterns of recurrence. Surgery. 1986;100:278-284.
18. Elias D, De Baere T, Roche A, Ducreux M, Leclere J, Lasser P. During liver regeneration following right portal embolization the growth rate of liver metastases is more rapid than that of the liver parenchyma. Br J Surg. 1999;86:784-788.
19. Rozga J, Tanaka N, Jeppsson B, Hagerstrand I, Bengmark S. Tumor growth in liver atrophy and growth: An experimental study in rats. Eur J Cancer Clin Oncol. 1985;21:135-140.
20. Panis Y, Nordlinger B, Delelo R, et al. Experimental colorectal liver metastases: Influence of sex, immunological status and liver regeneration. J Hepatol. 1990;11:53-57.
21. Picardo A, Karpoff HM, Ng B, Lee J, Brennan MF, Fong Y. Partial hepatectomy accelerates local tumor growth: Potential roles of local cytokine activation. Surgery. 1998;124:57-64.
22. Webber EM, Bruix J, Pierce RH, Fausto N. Tumor necrosis factor primes hepatocytes for DNA replication in the rat. Hepatology. 1998;28:1226-1234.
23. Akerman P, Cote P, Yang SQ, et al. Antibodies to tumor necrosis factor-alpha inhibit liver regeneration after partial hepatectomy. Am J Physiol. 1992;263:G579-G585.
24. Eggermont AM. TNF alpha in isolated perfusion systems: Success in the limb, developments for the liver credits, debits and future perspectives. Anticancer Res. 1998;18:3899-3905.
25. van Ijken MG, van Etten B, de Wilt JH, van Tiel ST, ten Hagen TL, Eggermont AM. Tumor necrosis factor-alpha augments tumor effects in isolated hepatic perfusion with melphalan in a rat sarcoma model. J Immunother. 2000;23:449-455.
26. Kohno H, Inokuchi K. Effects of postoperative adjuvant chemotherapy on liver regeneration in partially hepatectomized rats. Jpn J Surg. 1984;14:515-523.
27. Grosfeld JL, Weber TR, Baehner RL. Comparative toxicity of chemotherapy following partial hepatectomy. J Pediatr Surg. 1981;16:950-954.
28. Mizutani J, Hiraoka T, Yamashita R, Miyauchi Y. Promotion of hepatic metastases by liver resection in the rat. Br J Cancer. 1992;65:794-797.
29. Ahlman H, Westberg G, Wangberg B, et al. Treatment of liver metastases of carcinoid tumors. World J Surg. 1996;20:196-202.
30. Frilling A, Rogiers X, Malago M, Liedke OM, Kaun M, Broelsch CE. Treatment of liver metastases in patients with neuroendocrine tumors. Langenbecks Arch Surg. 1998;383:62-70.
31. De Jong M, Breeman WA, Bernard HF, et al. Therapy of neuroendocrine tumors with radiolabeled somatostatin-analogues. Q J Nucl Med. 1999;43:356-366.
32. Anderson CJ, Jones LA, Bass LA, et al. Radiotherapy, toxicity and dosimetry of copper-64-TETA-octreotide in tumor-bearing rats. J Nucl Med. 1998;39:1944-1951.
33. 90Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumours. Eur J Nucl Med. 1998;25:668-674.
34. 188Re-RC-160, a directly-radiolabeled somatostatin analogue. Int J Cancer. 1996;65:214-220.
35. Krenning EP, de Jong M, Kooij PP, et al. Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy. Ann Oncol. 1999;10:S23-S29.
36. Yamamoto K, Takenaka K, Matsumata T, Shimada M, Sugimachi K. The effect of octreotide on morphological hepatic regeneration and hepatic functional recovery after a two-thirds hepatectomy in rats. Hepatogastroenterology. 1999;46:1880-1884.
37. Pruthi RS, Farouk M, Tsai WH, Michalopoulos G, Meyers WC. The effect of octreotide on hepatic regeneration in rats. Surgery. 1993;113:84-89.
38. Michalopoulos GK, DeFrances MC. Liver regeneration. Science. 1997;276:60-66.
39. Reubi JC, Horisberger U, Laissue J. High density of somatostatin receptors in veins surrounding human cancer tissue: Role in tumor-host interaction? Int J Cancer. 1994;56:681-688.
40. Denzler B, Reubi JC. Expression of somatostatin receptors in peritumoral veins of human tumors. Cancer. 1999;85:188-198.